Increased T cell cytotoxicity by Betathine(TM)-induced upregulation of TNFα

International Journal of Immunopharmacology

Volumn 22, Issue 3, 2000, Pages 213-227

  Dunn, Thomas M ^a   Wormsley, Susan ^b   Taub, Floyd E ^c   Pontzer, Carol H ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b BD Technologies   (United States)

^c Dovetail Technologies Inc   (United States)

Author keywords

Betathine; Cytotoxicity; Tumor necrosis factor alpha

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; BETA ALANYLCYSTEAMINE DISULFIDE; BETATHINE; IONOMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOPHARMACOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CYSTEAMINE; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IONOMYCIN; MONOCYTES; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA, MESSENGER; T-LYMPHOCYTES; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033964267     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(99)00078-8     Document Type: Article

References (56)

1. Snell EE, Wittle EL, Moore JA. Alanylaminoethanemercapto compounds and methods for obtaining the same. United States Patent 2,722,551 (now United States Patent 2,680,767) Detroit, Parke, Davis & Co., 1955.
2. Knight G.D., Mann P.L., Laubscher K.H., Scallen T.J. Seemingly diverse activities of β-alethine. Cancer Res. 54:1994;5636-5642.
3. Knight G.D., Laubscher K.H., Fore M.L., Clark D.A., Scallen T.J. Vitalethine modulates erythropoiesis and neoplasia. Cancer Res. 54:1994;5623-5635.
4. Creighton T.E. Proteins. 1993;W. H. Freeman & Co, New York.
5. Ziegler D.M. Role of reversible oxidation-reduction of enzyme thiols-disulfides in metabolic regulation. Annu. Rev. Biochem. 54:1985;305-329.
6. Gilbert H.F. Molecular and cellular aspects of thiol-disulfide exchange. Adv. Enzymol. Metab. Relat. Areas. 63:1990;69-172.
7. Droge W., Eck P.P., Gmunder H., Mihm S. Molulation of lymphocyte functions and immune responses by cysteine and cysteine derivatives. Am. J. Med. 91:1991;140S-144S.
8. Cook J.A., Pass H.I., Iype S.N., Friedman N., DeGraff, et al. Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res. 51:1991;4287-4294.
9. Moertel C.G., Fleming T.R., MacDonald J.S., Haller D.G., Laurie J.A., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322:1990;352-358.
10. Amery W.K.P., Bruynseels J.P.J.M. Levamisole, the story and the lessons. Int. J. Immunopharmacol. 14:1992;481-486.
11. Martinez E, Domingo P. N-acetylcysteine as chemoprotectant in cancer chemotherapy. Lancet. 338:1991;249.
12. Albini A., D'Agostini P., Giunciuglio D., Paglieri I., Balansky R., et al. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int. J. Cancer. 61:1995;121-129.
13. Iwata S., Hori T., Sate N., Ueda-Taniguchi Y., Yamabe T., et al. Thiol-mediated redox regulation of lymphocyte proliferation. Possible involvement of adult T cell lekemia-derived factor and glutathione in transferrin receptor expression. J. Immunol. 152:1994;5633-5642.
14. Eylar E., Rivero-Quinones C., Molina C., Baez I., Molina F., et al. N-acetylcysteine enhances T cell functions and T cell growth in culture. Int. Immunol. 5:1993;97-101.
15. Liang C.M., Lee N., Cattell D., Liang S.M. Glutathione regulates interleukin-2 activity on cytotoxic T-cells. J. Biol. Chem. 264:1989;13519-13523.
16. Yim C.Y., Hibbs J.B., McGregor J.R., Galinsky R.E., Samlowski W.E. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J. Immunol. 152:1994;5796-5805.
17. Larrick J.W., Wright S.C. Cytotoxic mechanism of tumor necrosis factor-α FASEB J. 4:1990;3215-3223.
18. Aiyer R.A., Aggarwal B.B. Tumor necrosis factors. Podack E.R. CRC Handbook on cytolytic lymphocytes and complement: effectors of the immune system. 1988;105 CRC Press, Boca Raton.
19. Delneste Y., Jeannin P., Potier L., Romero P., Bonnefo J.-Y. N-acetyl-L-cysteine exhibits antitumoral activity by increasing tumor necrosis factor alpha-dependent T-cell cytotoxicity. Blood. 90:1977;1124-1132.
20. Philip P.A., Rea D., Thavasu P., Carmichael J., Stuart N.S., et al. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J. Natl Cancer Inst. 85:1993;1812-1818.
21. Wahl L.M., Katona I.M., Wilder R.L., Winter C.C., Haraoui B., et al. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). II. Functional properties of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions. Cell. Immunol. 85:1984;373-383.
22. Page M., Bejanoui N., Cinq-Marx B., Lemieux P. Optimization of the tetrazolium-based colorimetric assay for the measurement of cell number and cytotoxicity. Int. J. Immunopharmacol. 10:1988;785-793.
23. Goldfeld A.E., Strominger J.L., Doyle C. Human tumor necrosis factor α gene regulation in phorbol ester stimulated T and B cell lines. J. Exp. Med. 174:1991;73-81.
24. Ware C.F., Crowe P.D., Vanarsdale T.L., Andrews J.L., Grayson M.H., et al. Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. J. Immunol. 147:1991;4229-4238.
25. Black R.A., Rauch C.T., Kozlosly C.J., Peschon J.J., Slack J.L., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 35:1977;729-733.
26. Crowe P.D., Walter B.N., Mohler K.M., Otten-Evans C., Black R.A., et al. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J. Exp. Med. 181:1995;1205-1210.
27. Economou J.S., Rhoades K., Essner R., McBride W.H., Gasson J.C., et al. Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line. J. Exp. Med. 170:1989;321-326.
28. Udalova I.A., Knight J.C., Vidal V., Nedospasov S.A., Kwiatkowski D. Complex NF-κB interactions at the distal tumor necrosis factor promoter region in human monocytes. J. Biol. Chem. 273:1998;21178-21186.
29. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as a secondary antioxidant-responsive factor. EMBO J. 12:1993;2005-2015.
30. Lindstein T., June C.H., Ledbetter J.A., Stella G., Thompson C.B. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Sci. 244:1989;339-343.
31. Goldfeld A.E., Strominger J.L., Doyle C. Human tumor necrosis factor α gene regulation in phorbol ester stimulated T and B cell lines. J. Exp. Med. 174:1991;73-81.
32. Goeddel D.V., Aggarwal B.B., Gray P.W., Leung D.W., Nedwin G.E., et al. Tumor necrosis factors: gene structure and biological activities. Cold Spring Harbor symposia on quantitative biology. vol. 51:1986;597-609 Cold Spring Harbor Press, Cold Spring Harbor.
33. Sporn M.B., Roberts A.B. Transforming growth factor-β: multiple actions and potential clinical applications. JAMA. 262:1989;938-941.
34. Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X.F., et al. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol. 146:1991;1077-1082.
35. Grell M., Douni E., Wajant H., Lohden M., Clauss M., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 83:1995;793-802.
36. Decker T., Lohmann-Mattes M.L., Gifford G.E. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated macrophages. J. Immunol. 138:1987;957-962.
37. Kriegler M., Perez C., Defay K., Albert I., Lu S.D. A novel form of TNF/cachetin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 33:1988;45-53.
38. Perez C., Albert I., Defay K., Zachariades N., Gooding L., Kreigler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell. 63:1992;251-258.
39. Vassalli P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:1992;411-452.
40. Scheurich P., Thoma B., Ucer U., Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-α: induction of TNF receptors on human T cells and TNF-α-mediated enhancement of T cell responses. J. Immunol. 138:1987;1786-1790.
41. Ranges G., Bombara M., Aiyer R., Rice G., Palladino M. Tumor necrosis factor-α as a proliferative signal for an IL-2-dependent T cell line: strict species specificity of action. J. Immunol. 142:1989;1203-1208.
42. Robinet E., Branellec D., Termijtelen A.M., Blay J.Y., Gay F., et al. Evidence for tumor necrosis factor-α involvement in the optimal induction of class I allospecific cytotoxic T cells. J. Immunol. 144:1990;4555-4561.
43. Brockhaus M., Schoenfeld H.J., Schlaeger E.J., Hunzicker W., Lesslauer W., et al. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 87:1990;3127-3131.
44. Tartaglia L.A., Goeddel D.V., Reynolds C., Figari I.S., Webber R.F., et al. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J. Immunol. 151:1993;4637-4641.
45. Shalaby M.R., Sundan A., Loetscher H., Brockhaus M., Lesslauer W., et al. Binding of regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J. Exp. Med. 172:1990;1517-1520.
46. Naume B., Shalaby R., Lesslauer W., Espevik T. Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lympokine-activated killer cell activity and proliferation of natural killer cells. J. Immunol. 146:1991;3045-3048.
47. Rothe M., Sarms V., Dixit V.M. Goeddel DV. TRAF2-mediated activation of NF-kB by TNF receptor 2 and CD40. Sci. 269:1995;1424-1427.
48. Hsu H., Shu H.-B., Pan M.-G., Goeddel D.V. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 84:1996;299-308.
49. Tartaglia L.A., Ayres T.M., Wong G.H.W., Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell. 74:1993;845-853.
50. Baeuerle P.A., Henkel T. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12:1994;141-179.
51. Toledano M.B., Leonard W.J. Modulation of transcription factor NF-κB binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. USA. 88:1991;4328-4332.
52. Anderson M.T., Staal F.J.T., Gitler C., Herzenberg L.A., Herzenberg L.A. Separation of oxidant-initiated and redox-regulated steps in the NF-κB signal transduction pathway. Proc. Natl. Acad. Sci. USA. 91:1994;11527-11531.
53. Fox E.S., Leingang K.A. Inhibition of LPS-mediated activation in rat Kupffer cells by N-acetyl cysteine occurs subsequent to NF-κB translocation and requires protein synthesis. J. Leuk. Biol. 63:1998;509-514.
54. Tatsuta M., Iishi H., Yamamura H., Baba M., Mikuni T., Taniguchi H. Inhibitory effect of prolonged administration of cysteamine on experimental carcinogenesis in rat stomach induced by N-methyl-N′-nitro-N-nitrosoguanidine. Int. J. Cancer. 41:1988;423-426.
55. Fraker D.L., Alexander H.R. Pass HI. Biologic therapy with TNF. Systemic administration and isolation-perfusion. DeVita V.T., Hellman S., Rosenberg S.A. Biologic therapy of cancer. 1991;329 JB Lippincott, Philadelphia.
56. Miller L., Hunt J.S. Regulation of TNF-α production in activated mouse macrophages by progesterone. J. Immunol. 160:1988;5098-5104.